Reinsurance Group in C$5.8 Billion Coinsurance Deal With Canada's Manulife
By Robb M. Stewart
Reinsurance Group of America has struck a deal with Manulife Financial to reinsure roughly $4.4 billion of reserves, the third large block reinsurance transaction between the companies in what they say is the largest universal life reinsurance transaction in the Canadian market to date.
RGA's Canadian arm said it completed a coinsurance transaction with Manulife's Manufacturers Life Insurance unit to reinsure about 5.8 billion Canadian dollars of reserves, with an accompanied equivalent asset transfer.
The effective date of the transaction is April 1 and Manulife will continue to administer all policies as part of the arrangement.
The move comes after RGA last week said it reached an agreement with Japan Post Insurance for an affiliate of RGA to reinsure an about 700 billion yen ($4.62 billion) in-force block of individual life annuities through coinsurance.
Toronto-based Manulife said its deal with RGA Canada will see it reinsure reserves at a 16.2 times earnings multiple and about 1 times book value multiple. Manulife said that with the deal it expects to dispose of C$600 million of alternative long-duration assets.
The coinsurance transaction is expected to cut annual net income by about C$40 million, but result in a capital release of C$800 million, Manulife said.
It added it has approval from Canada's Office of the Superintendent of Financial Institutions to amend its existing normal course issuer bid, allowing it to buy back for cancellation up to 90 million shares, 40 million more than previously planned. Under the buyback program, which is set to expire Feb. 22, 2025, it has already bought almost 5 million shares.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
March 25, 2024 09:51 ET (13:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth